-+ 0.00%
-+ 0.00%
-+ 0.00%

RenovoRx Secures New U.S. Patent For RenovoRx, Novel Trans-Arterial Micro-Profusion Therapy Platform

Benzinga·05/06/2025 12:34:59
Listen to the news

Patent Expands Protection of TAMP therapy platform, Including Methods to Deliver an Agent, such as a Chemotherapeutic Drug, Near a Tumor

RenovoRx Currently Holds a Strong and Growing IP Portfolio with 19 Issued Patents and 12 Pending Patents Supporting the Commercialization of RenovoCath Device

RenovoRx, Inc. ("RenovoRx" or the "Company") (NASDAQ:RNXT), a life sciences company developing innovative targeted oncology therapies and commercializing RenovoCath®, a novel, FDA-cleared drug-delivery device, today announced that it has received an Issue Notification from the U.S. Patent and Trademark Office (USPTO) indicating that U.S. patent NO. 12,290,564, becomes effective today, May 6, 2025.